Stent thrombosis treatment: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| (3 intermediate revisions by 2 users not shown) | |||
| Line 6: | Line 6: | ||
Stents are usually placed in the proximal segments of major epicardial vessels, hence in-stent thrombotic occlusion clinically present as severe [[ischemia]] or [[STEMI|infarction]]<ref name="pmid11306525">{{cite journal| author=Cutlip DE, Baim DS, Ho KK, Popma JJ, Lansky AJ, Cohen DJ et al.| title=Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. | journal=Circulation | year= 2001 | volume= 103 | issue= 15 | pages= 1967-71 | pmid=11306525 | doi= | pmc= | url= }} </ref>. | Stents are usually placed in the proximal segments of major epicardial vessels, hence in-stent thrombotic occlusion clinically present as severe [[ischemia]] or [[STEMI|infarction]]<ref name="pmid11306525">{{cite journal| author=Cutlip DE, Baim DS, Ho KK, Popma JJ, Lansky AJ, Cohen DJ et al.| title=Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. | journal=Circulation | year= 2001 | volume= 103 | issue= 15 | pages= 1967-71 | pmid=11306525 | doi= | pmc= | url= }} </ref>. | ||
== | ==Treatment== | ||
* Emergent target lesion or target vessel [[revascularization]] is the treatment of choice in stent thrombosis to restore vessel patency. | * Emergent target lesion or target vessel [[revascularization]] is the treatment of choice in stent thrombosis to restore vessel patency. | ||
*Revascularization may be carried out by [[PCI]] or in some instances, [[thrombolytics]] if PCI is not available <ref name="pmid15728650">{{cite journal |author=Wenaweser P, Rey C, Eberli FR, Togni M, Tüller D, Locher S, Remondino A, Seiler C, Hess OM, Meier B, Windecker S |title=Stent thrombosis following bare-metal stent implantation: success of emergency percutaneous coronary intervention and predictors of adverse outcome |journal=[[European Heart Journal]] |volume=26 |issue=12 |pages=1180–7 |year=2005 |month=June |pmid=15728650 |doi=10.1093/eurheartj/ehi135 |url=http://eurheartj.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=15728650 |accessdate=2011-05-05}}</ref>. | *Revascularization may be carried out by [[PCI]] or in some instances, [[thrombolytics]] if PCI is not available <ref name="pmid15728650">{{cite journal |author=Wenaweser P, Rey C, Eberli FR, Togni M, Tüller D, Locher S, Remondino A, Seiler C, Hess OM, Meier B, Windecker S |title=Stent thrombosis following bare-metal stent implantation: success of emergency percutaneous coronary intervention and predictors of adverse outcome |journal=[[European Heart Journal]] |volume=26 |issue=12 |pages=1180–7 |year=2005 |month=June |pmid=15728650 |doi=10.1093/eurheartj/ehi135 |url=http://eurheartj.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=15728650 |accessdate=2011-05-05}}</ref>. | ||
*If revascularization is not successful, urgent [[CABG]] should be considered. | *If revascularization is not successful, urgent [[CABG]] should be considered. | ||
===The Underlying Cause of Stent Thrombosis Should Guide Management=== | |||
==The Underlying Cause of Stent Thrombosis Should Guide Management== | |||
The probable cause for stent thrombosis should be evaluated as the treatment varies with etiology. | The probable cause for stent thrombosis should be evaluated as the treatment varies with etiology. | ||
===Modifiable Procedural Related Causes=== | ====Modifiable Procedural Related Causes==== | ||
While the patient is undergoing cardiac catheterization, a careful evaluation should be undertaken to exclude procedure related variables that could be amenable to further treatment such as: | While the patient is undergoing cardiac catheterization, a careful evaluation should be undertaken to exclude procedure related variables that could be amenable to further treatment such as: | ||
*Suboptimal stent expansion and poor apposition, | |||
*Procedure-related variables of persistent dissection, total stent length, and final lumen diameter were significantly associated with the probability of stent thrombosis<ref name="pmid11306525">{{cite journal| author=Cutlip DE, Baim DS, Ho KK, Popma JJ, Lansky AJ, Cohen DJ et al.| title=Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. | journal=Circulation | year= 2001 | volume= 103 | issue= 15 | pages= 1967-71 | pmid=11306525 | doi= | pmc= | url= }} </ref>. | |||
===Modifiable Clinical Risk Factors=== | ====Modifiable Clinical Risk Factors==== | ||
Likewise, the patient should be questioned thoroughly for the following clinical risk factors for stent thrombosis: | Likewise, the patient should be questioned thoroughly for the following clinical risk factors for stent thrombosis: | ||
*Noncompliance with dual antiplatelet therapy, | |||
*Premature discontinuation of dual [[antiplatelet]] therapy | |||
====Clopidogrel Resistance: A Clinical Diagnosis of Exclusion==== | |||
===Clopidogrel Resistance: | |||
If neither angiographic, procedural nor clinical variables appear to play a role, then clopidogrel resistance should be considered. This diagnosis can of course be confirmed through platelet function testing and genetic testing. If this is the case consideration should be made to switching the patient to prasugrel.<ref name="pmid19249633">{{cite journal |author=Montalescot G, Wiviott SD, Braunwald E, Murphy SA, Gibson CM, McCabe CH, Antman EM |title=Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial |journal=[[Lancet]] |volume=373 |issue=9665 |pages=723–31 |year=2009 |month=February |pmid=19249633 |doi=10.1016/S0140-6736(09)60441-4 |url=http://linkinghub.elsevier.com/retrieve/pii/S0140-6736(09)60441-4 |issn= |accessdate=2010-06-30}}</ref> The TIMI 38 or TRITON trial demonstrated that newer antiplatelet agents such as [[prasugrel]]<ref name="pmid17982182">{{cite journal |author=Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM |title=Prasugrel versus clopidogrel in patients with acute coronary syndromes |journal=[[The New England Journal of Medicine]] |volume=357 |issue=20 |pages=2001–15 |year=2007 |month=November |pmid=17982182 |doi=10.1056/NEJMoa0706482 |url=http://content.nejm.org/cgi/pmidlookup?view=short&pmid=17982182&promo=ONFLNS19 |issn= |accessdate=2010-06-30}}</ref> may be used after weighing the risks of bleeding against benefits of decreased recurrence of stent thrombosis/coronary events. Patients who present with stent thrombosis after completing the recommended duration of treatment with [[clopidogrel]] restarting clopidogrel 75 mg daily along with [[aspirin]] and continuing for a minimum of one year should be considered. | If neither angiographic, procedural nor clinical variables appear to play a role, then clopidogrel resistance should be considered. This diagnosis can of course be confirmed through platelet function testing and genetic testing. If this is the case consideration should be made to switching the patient to prasugrel.<ref name="pmid19249633">{{cite journal |author=Montalescot G, Wiviott SD, Braunwald E, Murphy SA, Gibson CM, McCabe CH, Antman EM |title=Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial |journal=[[Lancet]] |volume=373 |issue=9665 |pages=723–31 |year=2009 |month=February |pmid=19249633 |doi=10.1016/S0140-6736(09)60441-4 |url=http://linkinghub.elsevier.com/retrieve/pii/S0140-6736(09)60441-4 |issn= |accessdate=2010-06-30}}</ref> The TIMI 38 or TRITON trial demonstrated that newer antiplatelet agents such as [[prasugrel]]<ref name="pmid17982182">{{cite journal |author=Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM |title=Prasugrel versus clopidogrel in patients with acute coronary syndromes |journal=[[The New England Journal of Medicine]] |volume=357 |issue=20 |pages=2001–15 |year=2007 |month=November |pmid=17982182 |doi=10.1056/NEJMoa0706482 |url=http://content.nejm.org/cgi/pmidlookup?view=short&pmid=17982182&promo=ONFLNS19 |issn= |accessdate=2010-06-30}}</ref> may be used after weighing the risks of bleeding against benefits of decreased recurrence of stent thrombosis/coronary events. Patients who present with stent thrombosis after completing the recommended duration of treatment with [[clopidogrel]] restarting clopidogrel 75 mg daily along with [[aspirin]] and continuing for a minimum of one year should be considered. | ||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
{{WS}} | {{WS}} | ||
{{WH}} | {{WH}} | ||
[[Category:Cardiology]] | |||
[[Category:Emergency medicine]] | |||
Latest revision as of 15:41, 5 March 2013
|
Coronary stent thrombosis Microchapters |
|
Epidemiology and Demographics |
|---|
|
Stent thrombosis treatment On the Web |
|
Risk calculators and risk factors for Stent thrombosis treatment |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editors-In-Chief: Smita Kohli, M.D.; Varun Kumar, M.B.B.S.; Lakshmi Gopalakrishnan, M.B.B.S.
Overview
Stents are usually placed in the proximal segments of major epicardial vessels, hence in-stent thrombotic occlusion clinically present as severe ischemia or infarction[1].
Treatment
- Emergent target lesion or target vessel revascularization is the treatment of choice in stent thrombosis to restore vessel patency.
- Revascularization may be carried out by PCI or in some instances, thrombolytics if PCI is not available [2].
- If revascularization is not successful, urgent CABG should be considered.
The Underlying Cause of Stent Thrombosis Should Guide Management
The probable cause for stent thrombosis should be evaluated as the treatment varies with etiology.
Modifiable Procedural Related Causes
While the patient is undergoing cardiac catheterization, a careful evaluation should be undertaken to exclude procedure related variables that could be amenable to further treatment such as:
- Suboptimal stent expansion and poor apposition,
- Procedure-related variables of persistent dissection, total stent length, and final lumen diameter were significantly associated with the probability of stent thrombosis[1].
Modifiable Clinical Risk Factors
Likewise, the patient should be questioned thoroughly for the following clinical risk factors for stent thrombosis:
- Noncompliance with dual antiplatelet therapy,
- Premature discontinuation of dual antiplatelet therapy
Clopidogrel Resistance: A Clinical Diagnosis of Exclusion
If neither angiographic, procedural nor clinical variables appear to play a role, then clopidogrel resistance should be considered. This diagnosis can of course be confirmed through platelet function testing and genetic testing. If this is the case consideration should be made to switching the patient to prasugrel.[3] The TIMI 38 or TRITON trial demonstrated that newer antiplatelet agents such as prasugrel[4] may be used after weighing the risks of bleeding against benefits of decreased recurrence of stent thrombosis/coronary events. Patients who present with stent thrombosis after completing the recommended duration of treatment with clopidogrel restarting clopidogrel 75 mg daily along with aspirin and continuing for a minimum of one year should be considered.
References
- ↑ 1.0 1.1 Cutlip DE, Baim DS, Ho KK, Popma JJ, Lansky AJ, Cohen DJ; et al. (2001). "Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials". Circulation. 103 (15): 1967–71. PMID 11306525.
- ↑ Wenaweser P, Rey C, Eberli FR, Togni M, Tüller D, Locher S, Remondino A, Seiler C, Hess OM, Meier B, Windecker S (2005). "Stent thrombosis following bare-metal stent implantation: success of emergency percutaneous coronary intervention and predictors of adverse outcome". European Heart Journal. 26 (12): 1180–7. doi:10.1093/eurheartj/ehi135. PMID 15728650. Retrieved 2011-05-05. Unknown parameter
|month=ignored (help) - ↑ Montalescot G, Wiviott SD, Braunwald E, Murphy SA, Gibson CM, McCabe CH, Antman EM (2009). "Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial". Lancet. 373 (9665): 723–31. doi:10.1016/S0140-6736(09)60441-4. PMID 19249633. Retrieved 2010-06-30. Unknown parameter
|month=ignored (help) - ↑ Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM (2007). "Prasugrel versus clopidogrel in patients with acute coronary syndromes". The New England Journal of Medicine. 357 (20): 2001–15. doi:10.1056/NEJMoa0706482. PMID 17982182. Retrieved 2010-06-30. Unknown parameter
|month=ignored (help)